Semaglutide (Ozempic)

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Ozempic: type 2 diabetes in adults
Product first approved 2018novonordisk.com
EU
  • Ozempic: type 2 diabetes mellitus
Product first approved 2018EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (48)
Atherosclerotic Cardiovascular Disease
Chronic Kidney Disease
NCT06058585 · The George Institute
2024-09-04 – 2029-12-31 · Chronic Kidney Diseases
What this study did
NCT04741074 · Geisinger Clinic
2021-07-23 – 2023-01-31 · CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
What this study did
Type 2 Diabetes
NCT07581145 · Ole Lander Svendsen
2026-04-24 – 2029-12 · Foot Ulcer Due to Type 2 Diabetes Mellitus
What this study did
NCT07428746 · Emory University
2026-05-07 – 2028-11 · Diabetes Mellitus, Type 2
What this study did
NCT03811561 · Novo Nordisk A/S
2019-05-08 – 2027-11-07 · Diabetes Mellitus, Type 2
What this study did
NCT07059377 · Ottawa Heart Institute Research Corporation
2026-02-13 – 2027-07 · Diabetes Mellitus, Type 2, Nicotine Addiction, Tobacco Dependence
What this study did
NCT05649137 · Novo Nordisk A/S
2023-01-04 – 2024-12-13 · Obesity, Diabetes Mellitus, Type 2
What this study did
NCT05816057 · Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
2022-07-25 – 2023-10-31 · Diabetes Mellitus, Type 2
What this study did
NCT05478252 · Novo Nordisk A/S
2022-08-03 – 2023-09-18 · Diabetes Mellitus, Type 2
What this study did
NCT06489457 · University Medical Centre Ljubljana
2020-09-20 – 2023-06-30 · Type 2 Diabetes Mellitus, Obesity, Functional Hypogonadism
What this study did
NCT03689374 · Novo Nordisk A/S
2018-10-01 – 2021-02-22 · Diabetes Mellitus, Type 2
What this study did
NCT04287179 · Novo Nordisk A/S
2020-03-09 – 2021-01-25 · Diabetes Mellitus, Type 2
What this study did
NCT03061214 · Novo Nordisk A/S
2017-08-28 – 2019-04-15 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03136484 · Novo Nordisk A/S
2017-03-15 – 2018-11-16 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03191396 · Novo Nordisk A/S
2017-06-27 – 2018-08-13 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03086330 · Novo Nordisk A/S
2017-03-15 – 2018-08-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02648204 · Novo Nordisk A/S
2016-01-06 – 2017-05-19 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02207374 · Novo Nordisk A/S
2014-08-04 – 2016-02-27 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02254291 · Novo Nordisk A/S
2014-10-02 – 2015-11-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07770282 · All India Institute of Medical Sciences, Bhubaneswar
2026-12-01 – 2030-12-30 · Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk, Insulin Resistance
What this study did
NCT05569772 · Universitaire Ziekenhuizen KU Leuven
2023-09-14 – 2030-05 · Glucose Intolerance After a Recent History of Gestational Diabetes
What this study did
NCT07218354 · VA Office of Research and Development
2026-07-28 – 2030-03-30 · Alcohol Use Disorder
What this study did
NCT06082063 · Steno Diabetes Center Copenhagen
2024-07-01 – 2029-07-01 · Cardiovascular Diseases, Heart Failure, Type 1 Diabetes, Kidney Failure
What this study did
NCT05305794 · Centre Hospitalier Universitaire Dijon
2022-07-12 – 2028-08 · Double Diabetes
What this study did
NCT05819853 · University of Colorado, Denver
2023-11-03 – 2028-06-30 · PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
What this study did
NCT06788626 · Wei Hu
2025-02 – 2028-02 · Acute Ischemic Stroke, Large Vessel Occlusion, Neuroprotective Drugs, Endovascular Treatment
What this study did
NCT07030621 · RenJi Hospital
2025-07-01 – 2028-01-31 · Acute Ischemic Stroke
What this study did
NCT05819138 · University of Colorado, Denver
2023-06-21 – 2027-12-01 · Diabetes Mellitus, Type 1
What this study did
NCT05586802 · Georgios Papadakis
2023-03-21 – 2027-04-30 · Klinefelter Syndrome
What this study did
NCT06894784 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2025-04 – 2027-01 · Diabetes Type 1
What this study did
NCT07820111 · Zagazig University
2025-10-18 – 2026-03-17 · Obese Diabetics, Obese Non Diabetic
What this study did
NCT05071417 · Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
2021-11 – 2025-12 · Atheroscleroses, Coronary
What this study did
NCT05891496 · Novo Nordisk A/S
2023-06-20 – 2025-09-08 · Alzheimers Disease
What this study did
NCT06361823 · Capital Medical University
2024-05-01 – 2025-01-01 · Idiopathic Intracranial Hypertension
What this study did
NCT04447859 · Tel-Aviv Sourasky Medical Center
2020-02-23 – 2022-09-10 · Diabetes type2
What this study did
Phase 2/3 (7)
Other / comorbidity
NCT07891156 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2026-10-13 – 2028-10-01 · Type 1 Diabetes, Overweight , Obesity
What this study did
NCT06387199 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2024-12-01 – 2027-12 · Type 1 Diabetes, Diabetes Mellitus
What this study did
Triple Therapy in T1DMactive not recruiting
NCT03899402 · State University of New York at Buffalo
2019-05-01 – 2026-06-30 · Type 1 Diabetes Mellitus
What this study did
NCT05646199 · University of Hull
2025-03-01 – 2025-12-30 · Polycystic Ovary Syndrome
What this study did
NCT06619015 · Esbjerg Hospital - University Hospital of Southern Denmark
2025-04-01 – 2025-04-01 · Obesity, Appetite Regulation, PreDiabetes
What this study did
NCT05788965 · University of Minnesota
2023-10-16 – 2024-12-31 · Cystic Fibrosis, Cystic Fibrosis-related Diabetes
What this study did
NCT05205928 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2022-10-02 – 2024-06-30 · Type 1 Diabetes, Diabetes Mellitus, Type 1
What this study did
Phase 2 (46)
Chronic Kidney Disease
NCT05822609 · University of Washington
2024-04-05 – 2027-12 · Diabetic Kidney Disease, Type 1 Diabetes
What this study did
Type 2 Diabetes
NCT05067621 · Yale University
2023-07-17 – 2027-01 · Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
What this study did
NCT04451837 · Region Skane
2020-09-10 – 2026-12-31 · Type2 Diabetes
What this study did
NCT06005012 · University of California, San Diego
2023-07-25 – 2026-12-31 · Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
What this study did
NCT06974825 · BrightGene Bio-Medical Technology Co., Ltd.
2023-08-30 – 2024-08-13 · Type 2 Diabetes
What this study did
NCT05486065 · Novo Nordisk A/S
2022-08-08 – 2023-12-13 · Diabetes Mellitus, Type 2
What this study did
NCT05144984 · Novo Nordisk A/S
2021-11-29 – 2023-03-23 · Diabetes Mellitus, Type 2
What this study did
NCT04143945 · Novo Nordisk A/S
2019-10-28 – 2020-01-04 · Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity
What this study did
NCT04007107 · Novo Nordisk A/S
2019-06-27 – 2019-09-04 · Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity
What this study did
NCT02461589 · Novo Nordisk A/S
2015-09-21 – 2016-10-13 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00696657 · Novo Nordisk A/S
2008-06-03 – 2009-02-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07204249 · San Francisco Department of Public Health
2026-02-26 – 2030-02-15 · Methamphetamine-dependence
What this study did
NCT07430332 · Children's Hospital Medical Center, Cincinnati
2027-09-01 – 2030-01-01 · Stage 1 Diabetes Mellitus, Type 1
What this study did
NCT07325500 · The University of Texas Health Science Center, Houston
2026-02-12 – 2029-06-30 · Weight Gain
What this study did
NCT07879612 · Massachusetts General Hospital
2027-01-10 – 2029-03-30 · Cannabis Use Disorder, Cue-reactivity
What this study did
NCT07227948 · The University of Texas Health Science Center, Houston
2026-01-15 – 2029-02-28 · Cocaine Use Disorder
What this study did
NCT07511543 · Population Health Research Institute
2026-10-31 – 2029-01-31 · Ischemic Stroke
What this study did
NCT07613437 · Chinese University of Hong Kong
2026-06-15 – 2028-12-31 · Intracerebral Hemorrhage
What this study did
NCT07614412 · Ministry of Health, Saudi Arabia
2027-01-01 – 2028-12-31 · Type 1 Diabetes Mellitus
What this study did
NCT06411210 · Yale University
2024-07-16 – 2028-06-30 · Diabetes type1, Obesity
What this study did
NCT07523633 · Anders Fink-Jensen, MD, DMSci
2026-04-30 – 2028-04-30 · Cannabis Use Disorder, Cannabis Use Disorders, Cannabis Abuse, Cannabis Dependence, Cannabis Addiction
What this study did
NCT07202247 · City of Hope Medical Center
2025-11-05 – 2028-04-09 · Prostate Carcinoma, Recurrent Prostate Carcinoma
What this study did
NCT05938712 · University Health Network, Toronto
2023-10-24 – 2028-03-01 · Kidney Transplant Recipients
What this study did
NCT05630586 · Aarhus University Hospital
2023-04-12 – 2027-12 · Acute Ischemic Stroke
What this study did
NCT06639464 · Brigham and Women's Hospital
2025-06-02 – 2027-09-15 · Opioid Use Disorder
What this study did
NCT06691243 · University of Maryland, Baltimore
2025-08-07 – 2027-07 · Cocaine Use Disorder, HIV
What this study did
NCT07040592 · Yale University
2026-01-15 – 2027-06-30 · Alcohol Use Disorder (AUD), HIV
What this study did
NCT06548490 · Milton S. Hershey Medical Center
2025-01-27 – 2027-04-30 · Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
What this study did
NCT06015893 · National Institute on Drug Abuse (NIDA)
2023-10-17 – 2027-03-31 · Addiction, Alcohol Use Disorder
What this study did
NCT07509112 · Kirby Institute
2026-09 – 2027-03 · Methamphetamine Use Disorder
What this study did
Semaglutide in Auto-HSCTnot yet recruiting
NCT06449625 · Klaus Gottlob Müller
2024-08-12 – 2027-02-01 · Intestinal Mucositis, Inflammation, Chemotherapeutic Toxicity
What this study did
NCT05424003 · University of Virginia
2024-02-22 – 2026-08-01 · NAFLD
What this study did
NCT07610174 · Kafrelsheikh University
2025-06-02 – 2026-04-29 · Heart Failure, Heart Valve Prosthesis
What this study did
NCT07871799 · Sheba Medical Center
2025-11-17 – 2026-02-25 · Healthy Aging
What this study did
NCT06762314 · Mostafa Bahaa
2025-01-20 – 2026-01-20 · Diabetes
What this study did
NCT06409130 · Novo Nordisk A/S
2024-05-20 – 2026-01-12 · Alcohol-related Liver Disease
What this study did
NCT05891587 · Oklahoma State University Center for Health Sciences
2023-07-07 – 2025-10-01 · Alcohol Use Disorder
What this study did
NCT03659682 · Oslo University Hospital
2019-01-02 – 2024-12-31 · Parkinson Disease
What this study did
NCT04466345 · University Health Network, Toronto
2021-10-06 – 2024-12-27 · Major Depressive Disorder
What this study did
NCT05920889 · Chinese University of Hong Kong
2023-08-01 – 2024-10-25 · Stroke, Stroke, Acute, Stroke, Ischemic, Brain Diseases
What this study did
NCT05537233 · Viral N. Shah
2023-04-11 – 2024-08-06 · Type 1 Diabetes, Obesity
What this study did
NCT05530577 · University of North Carolina, Chapel Hill
2022-10-07 – 2024-05-13 · Tobacco Use Disorder, Nicotine Addiction
What this study did
NCT05193578 · Jan Frystyk
2022-01-01 – 2024-05-01 · Schizophrenia, Prediabetic State
What this study did
NCT05520775 · University of North Carolina, Chapel Hill
2022-09-02 – 2024-04-19 · Alcohol Use Disorder, Cigarette Smoking
What this study did
NCT04216589 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-02-19 – 2023-09-15 · HIV Infections, Non-Alcoholic Fatty Liver Disease
What this study did
NCT04615871 · Vladimír Džavík
2021-09-10 – 2022-03-31 · Covid19, Myocardial Injury
What this study did
Phase 1/2 (5)
Type 2 Diabetes
NCT07563699 · Mapi Pharma Ltd.
2026-08-09 – 2028-06 · Diabete Type 2
What this study did
NCT07374328 · Second Affiliated Hospital of Guangzhou Medical University
2025-06-01 – 2026-08-31 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07651319 · The Methodist Hospital Research Institute
2026-09-01 – 2029-12 · Alzheimer Dementia (AD)
What this study did
NCT06057077 · Ministry of Health, Saudi Arabia
2024-01-01 – 2024-12-31 · Type 1 Diabetes
What this study did
NCT04702516 · Morten Frost
2021-03-24 – 2022-08-31 · Osteopenia
What this study did
Phase 1 (55)
Type 2 Diabetes
NCT05071898 · University of Maryland, Baltimore
2022-04-11 – 2028-04 · Obesity, Diabetes Type 2
What this study did
NCT06403761 · Novo Nordisk A/S
2024-05-06 – 2026-02-02 · Diabetes Mellitus, Type 2
What this study did
NCT06642584 · Novo Nordisk A/S
2024-10-15 – 2025-08-13 · Healthy Volunteers Type 2 Diabetes
What this study did
NCT06422624 · Bostal Drug Delivery Co., Ltd
2024-08 – 2024-11 · Diabetes Mellitus, Type 2
What this study did
NCT04032197 · Novo Nordisk A/S
2019-08-12 – 2023-06-06 · Diabetes Mellitus, Type 2
What this study did
NCT05689099 · Novo Nordisk A/S
2023-01-17 – 2023-05-30 · Diabetes Mellitus, Type 2, Healthy Participants
What this study did
NCT05129891 · Novo Nordisk A/S
2021-11-03 – 2023-05-04 · Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes
What this study did
NCT05435677 · Novo Nordisk A/S
2022-06-22 – 2023-04-25 · Diabetes Mellitus, Type 2
What this study did
NCT05249881 · Aga Khan University
2022-03-10 – 2022-12 · Diabetes Mellitus, Type 2, Weight Change, Body
What this study did
NCT05498610 · Novo Nordisk A/S
2022-08-11 – 2022-10-12 · Diabetes Mellitus, Type 2
What this study did
NCT05153564 · Novo Nordisk A/S
2021-12-13 – 2022-09-01 · Diabetes Mellitus, Type 2
What this study did
NCT05232708 · Novo Nordisk A/S
2022-01-19 – 2022-08-30 · Healthy Volunteers (Diabetes Mellitus, Type 2)
What this study did
NCT04259801 · Novo Nordisk A/S
2020-02-17 – 2022-03-16 · Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2
What this study did
NCT05046873 · Novo Nordisk A/S
2021-09-06 – 2022-01-05 · Diabetes Mellitus, Type 2
What this study did
NCT04878406 · Novo Nordisk A/S
2021-05-18 – 2021-07-20 · Healthy Volunteers Type 2 Diabetes
What this study did
NCT04152915 · Novo Nordisk A/S
2019-11-25 – 2020-05-25 · Healthy Volunteers, Diabetes Mellitus, Type 2
What this study did
NCT03789578 · Novo Nordisk A/S
2019-01-17 – 2019-10-10 · Diabetes Mellitus, Type 2
What this study did
NCT03598621 · Novo Nordisk A/S
2018-07-23 – 2019-01-17 · Diabetes Mellitus, Type 2
What this study did
NCT03638778 · Novo Nordisk A/S
2018-08-17 – 2018-12-05 · Diabetes Mellitus, Type 2
What this study did
NCT03288740 · Novo Nordisk A/S
2017-09-21 – 2018-08-07 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03466567 · Novo Nordisk A/S
2018-03-15 – 2018-07-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02147431 · Novo Nordisk A/S
2014-05-21 – 2015-05-20 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02212067 · Novo Nordisk A/S
2014-08-11 – 2015-05-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02146079 · Novo Nordisk A/S
2014-05-21 – 2014-10-20 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT02022254 · Novo Nordisk A/S
2013-12-17 – 2014-08-28 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01866748 · Novo Nordisk A/S
2013-05 – 2014-04 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01686945 · Novo Nordisk A/S
2012-09-19 – 2013-04-08 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01572753 · Novo Nordisk A/S
2012-04-12 – 2012-09-08 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01324505 · Novo Nordisk A/S
2011-03 – 2012-01 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01272973 · Novo Nordisk A/S
2011-01 – 2011-07 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT00833716 · Novo Nordisk A/S
2009-02-02 – 2010-07-26 · Diabetes, Diabetes Mellitus, Type 2, Renal Impairment
What this study did
NCT00813020 · Novo Nordisk A/S
2009-01 – 2009-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03144271 · Novo Nordisk A/S
2007-06-11 – 2007-10-08 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
Other / comorbidity
NCT07772960 · Yale University
2026-10-01 – 2031-10-31 · Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)
What this study did
NCT07627191 · University of Arizona
2026-10-07 – 2028-06-30 · Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma
What this study did
NCT06222437 · Methodist Health System
2026-02 – 2027-02 · Polycystic Ovary Syndrome
What this study did
NCT07223983 · Yale University
2026-03-26 – 2027-02 · Alcohol Use Disorder, Weight Loss, Bariatric Surgery Patients
What this study did
NCT07087795 · Novo Nordisk A/S
2025-07-01 – 2026-09-25 · Diabetes Mellitus, Type 1
What this study did
NCT06149260 · Second Xiangya Hospital of Central South University
2024-02-29 – 2024-12 · Scleroderma, Systemic, Fibrosis, Semaglutide
What this study did
NCT06699329 · Merck Sharp & Dohme LLC
2024-01-22 – 2024-05-24 · Healthy
What this study did
NCT05996874 · Novo Nordisk A/S
2023-08-12 – 2024-04-18 · Healthy Participants
What this study did
NCT06097390 · Novo Nordisk A/S
2023-09-28 – 2024-03-27 · Healthy Participants
What this study did
NCT05429593 · Novo Nordisk A/S
2022-06-22 – 2023-04-13 · Healthy Volunteers
What this study did
NCT03357380 · Novo Nordisk A/S
2017-11-28 – 2020-03-20 · Hepatobiliary Disorders, Non-alcoholic Fatty Liver Disease
What this study did
NCT02557620 · Novo Nordisk A/S
2015-09 – 2016-04 · Diabetes, Healthy
What this study did
NCT02064348 · Novo Nordisk A/S
2014-02-26 – 2015-04-23 · Diabetes, Healthy
What this study did
NCT02243098 · Novo Nordisk A/S
2014-09-16 – 2015-04-07 · Diabetes, Healthy
What this study did
NCT02079870 · Novo Nordisk A/S
2014-03-06 – 2015-01-07 · Diabetes, Metabolism and Nutrition Disorder, Obesity
What this study did
Phase 4 (52)
Atherosclerotic Cardiovascular Disease
NCT07617155 · Peking Union Medical College Hospital
2026-09 – 2028-12 · Hypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis, Pancreatitis Relapsing, Hypertriglyceridemia
What this study did
NCT07073053 · Taipei Veterans General Hospital, Taiwan
2025-10-01 – 2028-07-31 · Glucagon-Like Peptide-1 Receptor Agonists, Type 2 Diabetes, Coronary Arterial Disease (CAD)
What this study did
NCT05870462 · Canadian Medical and Surgical Knowledge Translation Research Group
2023-04-29 – 2024-12 · Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Obesity
What this study did
NCT03985384 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
2019-04-30 – 2022-12-27 · Type 2 Diabetes, Coronary Artery Disease
What this study did
Chronic Kidney Disease
NCT07900438 · Novo Nordisk A/S
2026-10-12 – 2030-01-24 · Cardiovascular Risk, Chronic Kidney Disease
What this study did
NCT07547878 · Baylor Research Institute
2026-04-08 – 2029-03-31 · Chronic Kidney Disease, Type 2 Diabetes
What this study did
DIALYSIS-TIR Studyactive not recruiting
NCT06042153 · University of Texas Southwestern Medical Center
2023-12-05 – 2028-09 · Type 2 Diabetes, End Stage Renal Disease on Dialysis
What this study did
NCT07239570 · Peter Rossing
2025-06-20 – 2028-06 · Chronic Kidney Disease(CKD)
What this study did
NCT07017270 · Unity Health Toronto
2025-11-27 – 2027-09 · Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)
What this study did
NCT06954090 · Steno Diabetes Center Copenhagen
2025-11-20 – 2027-05-31 · Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria
What this study did
Type 2 Diabetes
NCT07485062 · Western University, Canada
2026-09-01 – 2029-05-01 · Type 2 Diabetes, Cognitive Decline in Older Adults
What this study did
NCT06706284 · Marzieh Salehi
2025-04-11 – 2029-03-01 · Spinal Cord Injuries, Type 2 Diabetes
What this study did
NCT06461377 · The First Affiliated Hospital with Nanjing Medical University
2024-06-13 – 2027-12-31 · Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
What this study did
NCT07314684 · Federico II University
2025-09-08 – 2027-03-08 · T2DM (Type 2 Diabetes Mellitus)
What this study did
NCT05780905 · University of Washington
2024-01-11 – 2026-12-31 · Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
What this study did
NCT07165158 · The First Affiliated Hospital of Xiamen University
2025-09-15 – 2026-12-31 · Osteoporosis, Osteoporosis Fracture, T2DM
What this study did
NCT04892199 · Anders Fink-Jensen, MD, DMSci
2021-09-01 – 2026-08-01 · Metabolic Disturbance, Schizophrenia, Type 2 Diabetes, Clozapine, GLP-1, Olanzapine
What this study did
NCT07272343 · Second Affiliated Hospital of Nanchang University
2023-02-10 – 2026-07-01 · Type 2 Diabetes Mellitus (T2DM), Semaglutide, Caloric Restriction
What this study did
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
2025-05-26 – 2026-06-30 · Diabetes Mellitus Type 2
What this study did
NCT04639414 · German Diabetes Center
2021-03-26 – 2025-11-17 · Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
What this study did
NCT04854083 · Kirsi Pietiläinen
2022-02-17 – 2025-08 · Type2 Diabetes
What this study did
NCT04126603 · Sabyasachi Sen
2019-08-01 – 2025-05-14 · Diabetes Mellitus, Type 2
What this study did
NCT05303857 · University of Erlangen-Nürnberg Medical School
2022-03-03 – 2025-04-17 · Diabetes Mellitus, Type 2
What this study did
NCT06243536 · University Hospital Sestre Milosrdnice
2024-02-01 – 2024-12-31 · Type 2 Diabetes, Overweight, Disordered Eating Behaviors
What this study did
NCT04979130 · University of Colorado, Denver
2022-01-01 – 2024-10-16 · Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
What this study did
NCT06475586 · University of Banja Luka
2023-05-03 – 2024-06-10 · Psoriasis Vulgaris, Diabetes Type 2
What this study did
NCT05786521 · The University of Texas Health Science Center at San Antonio
2023-04-01 – 2024-05-20 · Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
What this study did
NCT05597202 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2023-01-01 – 2024-04 · Type 2 Diabetes
What this study did
NCT05533632 · Novo Nordisk A/S
2022-04-25 – 2024-01-18 · Diabetes Mellitus, Type 2
What this study did
NCT04538352 · The Cleveland Clinic
2021-01-18 – 2023-11-01 · Type 2 Diabetes
What this study did
NCT05606471 · University of Nottingham
2021-09-15 – 2023-07-28 · Type 2 Diabetes Mellitus in Obese
What this study did
NCT07732218 · Rehman Medical Institute - RMI
2022-07-04 – 2023-03-30 · Type 2 Diabetes
What this study did
NCT04624672 · Geisinger Clinic
2021-08-25 – 2022-08-17 · Diabetes Mellitus, Type 2
What this study did
NCT04061200 · Steno Diabetes Center Copenhagen
2019-11-01 – 2021-08-01 · Type 2 Diabetes With Renal Manifestations
What this study did
NCT04189848 · Novo Nordisk A/S
2019-12-03 – 2020-02-27 · Healthy Volunteers, Diabetes Mellitus, Type 2, Overweight, Obesity
What this study did
NCT03724981 · Eli Lilly and Company
2018-10-18 – 2019-04-12 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07361874 · University of Texas Southwestern Medical Center
2026-03-05 – 2030-05-31 · Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
What this study did
NCT07389941 · University of Luebeck
2026-10 – 2029-04 · Atrial Fibrillation (AF)
What this study did
NCT06986993 · University of Oklahoma
2024-07-01 – 2028-06-30 · Tobacco Use
What this study did
NCT07483801 · Cambridge University Hospitals NHS Foundation Trust
2026-03 – 2028-04 · Cardiovascular Diseases
What this study did
NCT06908694 · Hamilton Health Sciences Corporation
2025-07-02 – 2027-10-31 · Prostate Cancer
What this study did
NCT06184633 · Rijnstate Hospital
2024-07-21 – 2027-05-01 · Atrial Fibrillation, Obesity, Weight Loss
What this study did
NCT07251556 · Chinese University of Hong Kong
2025-12-01 – 2027-01-01 · Psoriasis Arthritis
What this study did
NCT06959784 · China-Japan Friendship Hospital
2024-01-01 – 2026-12-31 · Diabetes Mellitus, Cardiovascular Diseases, Cerebrovascular Disease
What this study did
NCT07513168 · Asian Institute Of Medical Sciences
2025-08-01 – 2026-12-01 · Obesity, Weight Reduction, Cardiometabolic Risk Factors
What this study did
NCT05119179 · The University of Texas Health Science Center, Houston
2021-11-22 – 2026-10-31 · PreDiabetes
What this study did
NCT07254715 · Ain Shams University
2026-01-01 – 2026-07-30 · Semaglutide-Induced Gastric Motility, Anesthesia
What this study did
NCT04873050 · Woman's
2022-01-13 – 2026-03-01 · Pre Diabetes, Postpartum Disorder
What this study did
NCT05813249 · Zagazig University
2023-02-15 – 2024-04-01 · Non-alcoholic Fatty Liver Disease
What this study did
Early phase / not applicable (20)
Chronic Kidney Disease
NCT06555146 · Bispebjerg Hospital
2024-08 – 2025-03 · Diabetes Mellitus, Type 2, Kidney Disease, Chronic
What this study did
Type 2 Diabetes
NCT05501483 · Karolinska Institutet
2023-02-08 – 2032-12-31 · Type 2 Diabetes
What this study did
NCT07065383 · University of Aberdeen
2025-08-01 – 2028-07-31 · Diabetes Mellitus Type 2
What this study did
NCT07317115 · GT Metabolic Solutions, Inc.
2026-03-18 – 2028-06 · Obesity (Disorder), Obesity & Overweight, Type 2 Diabetes (T2DM)
What this study did
NCT07677995 · University of Ulster
2026-09 – 2027-02 · Type 2 Diabetes, Cardiovascular Disease, Omega-3 Fatty Acids
What this study did
NCT07570810 · Shanghai Jiao Tong University School of Medicine
2026-06-01 – 2026-12-31 · Type 2 Diabetes, Obesity, Non-alcoholic Fatty Liver Disease
What this study did
NCT07847593 · Nordic Biotic Sp. z o.o.
2025-07-09 – 2026-07-15 · Obesity (Disorder), GLP-1 Receptor Agonist Treatment, Probiotic Intervention, Diabetes Mellitus Type 2
What this study did
NCT05984238 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2023-08-03 – 2026-05-28 · Diabetes Mellitus, Type 2
What this study did
NCT05779644 · RenJi Hospital
2023-02-23 – 2025-02-23 · Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2, Abdominal Fat, Non-Alcoholic Fatty Liver Disease, Metabolism Disorder, Glucose, Metabolism Disorder, Lipid
What this study did
NCT05078255 · Asger Lund, MD
2022-01-27 – 2025-01-24 · Type 2 Diabetes, Obesity
What this study did
NCT06629688 · University Hospital Dubrava
2023-11-01 – 2024-04-01 · Diabetes Mellitus Type 2, Iron Absorption
What this study did
NCT05990374 · Nanjing First Hospital, Nanjing Medical University
2023-08-01 – 2024-01-01 · Diabetes
What this study did
NCT04383197 · University of Copenhagen
2019-12-10 – 2022-08 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07586150 · Ludwig-Maximilians - University of Munich
2028-10 – 2030-12 · Severe Mental Illness, Depression / Major Depressive Disorder, Bipolar Disorder (BD), Schizophrenia
What this study did
NCT07874932 · Morten Hostrup, PhD
2026-10-14 – 2028-04-30 · Caloric Restriction, Body Composition, Performance
What this study did
NCT07874971 · Morten Hostrup, PhD
2026-10-14 – 2028-04-30 · Caloric Restriction, Body Composition, Performance
What this study did
NCT06608433 · University Hospital, Basel, Switzerland
2025-01-16 – 2025-11-30 · Healthy Volunteer Study, HPA, Cortisol Deficiency, Adrenal Insufficiency
What this study did
NCT06292065 · Nils Vlaeminck
2024-04-16 – 2025-05-31 · Gastroparesis
What this study did
NCT06363487 · University of Oxford
2024-06-06 – 2024-12-11 · Cognitive Change
What this study did
NCT05390307 · Dasman Diabetes Institute
2023-04-01 – 2024-01-01 · Type 1 Diabetes
What this study did
Used as active comparator (43)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (23)
Type 2 Diabetes
NCT07046273 · Shandong New Time Pharmaceutical Co., LTD
2025-08-01 – 2029-02-01 · Type 2 Diabetes (T2DM)
What this study did
NCT07400107 · Novo Nordisk A/S
2026-05-20 – 2028-12-19 · Obesity, Overweight, Diabetes Mellitus, Type 2
What this study did
NCT07866066 · Amgen
2026-10-16 – 2028-12-05 · Diabetes Mellitus, Type 2
What this study did
NCT07743983 · BrightGene Bio-Medical Technology Co., Ltd.
2026-09-17 – 2028-11-30 · Type 2 Diabetes (T2DM)
What this study did
NCT07653477 · The United Bio-Technology (Hengqin) Co., Ltd.
2026-09-07 – 2028-02-29 · Type 2 Diabetes
What this study did
NCT07628985 · Carnot Laboratories
2026-09 – 2027-10 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07064486 · BrightGene Bio-Medical Technology Co., Ltd.
2025-07-04 – 2027-04-30 · Type 2 Diabetes (T2DM)
What this study did
NCT06260722 · Eli Lilly and Company
2024-02-21 – 2027-02 · Diabetes Mellitus, Type 2
What this study did
NCT07139548 · Guangdong Raynovent Biotech Co., Ltd
2025-08-31 – 2026-12-31 · T2DM
What this study did
NCT06778967 · Gan & Lee Pharmaceuticals.
2025-02-13 – 2026-09-18 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06716216 · BrightGene Bio-Medical Technology Co., Ltd.
2025-01-13 – 2026-08-25 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06649344 · Fujian Shengdi Pharmaceutical Co., Ltd.
2024-10-31 – 2026-07-18 · Type 2 Diabetes
What this study did
NCT06184568 · Innovent Biologics (Suzhou) Co. Ltd.
2024-02-29 – 2026-02-09 · Type 2 Diabetes, Obesity
What this study did
NCT06339086 · Chengdu Brilliant Pharmaceutical Co., Ltd.
2024-04 – 2025-12-30 · Type 2 Diabetes Mellitus
What this study did
NCT06045221 · Eli Lilly and Company
2023-09-22 – 2025-08-22 · Type 2 Diabetes
What this study did
NCT06161844 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2024-02-23 – 2025-05-14 · Type 2 Diabetes Mellitus
What this study did
NCT06739044 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2023-09-20 – 2025-02-21 · Type 2 Diabetes
What this study did
NCT05950516 · Qilu Pharmaceutical Co., Ltd.
2023-07-10 – 2025-01-22 · Type 2 Diabetes
What this study did
NCT03987919 · Eli Lilly and Company
2019-07-30 – 2021-02-15 · Type 2 Diabetes
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06975111 · University of Colorado, Denver
2026-03-01 – 2030-10-01 · Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
What this study did
Phase 2 (12)
Chronic Kidney Disease
NCT06717698 · Novo Nordisk A/S
2024-12-02 – 2026-09-17 · Chronic Kidney Disease
What this study did
NCT04515849 · AstraZeneca
2020-08-31 – 2022-03-08 · Type 2 Diabetes Mellitus, Chronic Kidney Diseases
What this study did
Type 2 Diabetes
NCT07112872 · Hoffmann-La Roche
2025-08-19 – 2028-02-05 · Type 2 Diabetes Mellitus
What this study did
NCT07923357 · Shenzhen Salubris Pharmaceuticals Co., Ltd.
2026-10-30 – 2027-11-30 · Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, T2DM
What this study did
NCT07668388 · Novo Nordisk A/S
2026-06-22 – 2027-11-15 · Diabetes Mellitus, Type 2
What this study did
NCT07415954 · Novo Nordisk A/S
2026-04-17 – 2027-10-01 · Diabetes Mellitus, Type 2
What this study did
NCT07187856 · ProGen. Co., Ltd.
2026-01 – 2026-12 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07163624 · The United Bio-Technology (Hengqin) Co., Ltd.
2025-03-22 – 2025-12-30 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06579105 · AstraZeneca
2024-10-08 – 2025-12-19 · Diabetes Mellitus, Type 2
What this study did
NCT06256549 · Gan and Lee Pharmaceuticals, USA
2023-08-09 – 2024-07-20 · Type 2 Diabetes
What this study did
NCT04153929 · Boehringer Ingelheim
2020-04-30 – 2021-11-04 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT06072963 · Rutgers, The State University of New Jersey
2024-01-30 – 2028-12-01 · Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome
What this study did
Phase 1 (5)
Type 2 Diabetes
NCT06982859 · Eli Lilly and Company
2025-06-02 – 2027-01 · Diabetes Mellitus, Insulin Sensitivity
What this study did
NCT05670379 · Vivani Medical, Inc
2024-12-20 – 2025-08-21 · Overweight and Obesity, Type2diabetes
What this study did
NCT06634927 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2024-09-22 – 2025-02-12 · Type 2 Diabetes
What this study did
NCT03951753 · Eli Lilly and Company
2019-06-28 – 2021-04-08 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT06497049 · Geropharm
2023-06-30 – 2024-05-05 · Pharmacokinetics, Safety Issues, Bioequivalence
What this study did
Early phase / not applicable (2)
Type 2 Diabetes
NCT07713992 · Tianjin Medical University
2026-09-15 – 2028-02-01 · Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
What this study did
Studied as part of a combination product (8)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (7)
Type 2 Diabetes
NCT07282613 · Novo Nordisk A/S
2026-08-04 – 2030-03-30 · Diabetes Mellitus, Type 2
What this study did
NCT05394519 · Novo Nordisk A/S
2023-02-01 – 2025-02-03 · Overweight, Obesity, Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT05669755 · Novo Nordisk A/S
2023-03-01 – 2027-10-14 · Cardiovascular Disease
What this study did
Phase 2 (1)
Type 2 Diabetes
NCT06797869 · Novo Nordisk A/S
2025-01-29 – 2026-08-05 · Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Chronic Kidney Disease
NCT05897372 · Iain Bressendorff
2023-08-01 – 2024-09-23 · Diabetic Kidney Disease
What this study did
Type 2 Diabetes
NCT07172867 · Halia Therapeutics, Inc.
2026-01-06 – 2026-01-23 · Diabetes Mellitus, Type 2, Obesity
What this study did
Early phase / not applicable (1)
Type 2 Diabetes
NCT07599046 · Eighth Affiliated Hospital, Sun Yat-sen University
2026-04-30 – 2029-12-30 · Obesity Type 2 Diabetes Mellitus
What this study did

Competitive landscape

This mechanism is crowded: 50 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Atherosclerotic Cardiovascular Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Semaglutide (Ozempic): this drugApprovedPeptideGLP-1 receptorReliable signal
NCT04560998: Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Weak signal
NCT03510884: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7)
NCT01709500: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis (From Baseline to Week 52): Alirocumab 75 mg/up to 150 mg -48.7 percent change (Standard Error 1.9) vs Placebo 2.8 percent change (Standard Error 2.8)
Bempedoic Acid (Nexletol)ApprovedSmall moleculeATP citrate lyasePartial signal
NCT02991118: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid -15.07 percent change (Standard Error 1.073) vs Placebo 2.35 percent change (Standard Error 1.446)
NCT02988115: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline; Week 12): Bempedoic Acid -22.58% (Standard Error 1.29) vs Placebo -1.17% (Standard Error 1.421)
Bempedoic Acid / Ezetimibe (Nexlizet)ApprovedSmall moleculeATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Partial signal
NCT03337308: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC -36.2% (Standard Error 2.56) vs Bempedoic Acid 180 mg -17.2% (Standard Error 2.52) vs Ezetimibe 10 mg -23.2% (Standard Error 2.18) vs Placebo 1.8% (Standard Error 3.49)
Cangrelor (Kengreal)ApprovedSmall moleculeP2Y12 receptorPartial signal
NCT00385138: Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). missed
Colchicine (cardiovascular) (Lodoco)ApprovedSmall moleculeMicrotubule/inflammasome (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
Evolocumab (Repatha)ApprovedMonoclonal antibodyPCSK9Partial signal
NCT02392559: Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08)
NCT02207634: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877)
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1Reliable signal
NCT00202878: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81)
NCT00110435: Percent reduction in LDL-C from baseline at 6 weeks: ezetimibe/simvastatin 10/20mg -53.6% vs atorvastatin 10mg -38.3% (P<.001) and vs atorvastatin 20mg -44.6% (P<.001); ezetimibe/simvastatin 10/40mg -57.6% vs atorvastatin 40mg -50.9% (P<.001). Primary endpoint (percent change from baseline in LDL-C) significantly favored ezetimibe/simvastatin at both dose comparisons.
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090
Liraglutide (Saxenda)
Approved(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy Tablets)
Approved(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorPartial signalFeatured results are non-efficacy only in this race
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
AG2304Phase 3Small moleculeHMG-CoA reductase / NPC1L1Partial signalNo reviewed efficacy summary in this indication
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet graded
NCT01263925: ClinicalTrials.gov results section for NCT01263925 ('Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication', UCB Pharma, Phase 3, enrollment 561/541 FAS, completed April 2011 -- matches this record exactly). Primary outcome: pain-free walking-distance ratio vs active comparator (pentoxifylline) across three periods; both treatments produced similar improvements with no clear superiority of either. phase 3 result · pivotal pending
Amlodipine / Valsartan / Atorvastatin (CJ-30061)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasePartial signalNo reviewed efficacy summary in this indication
Beperminogene Perplasmid (HGF Plasmid) (Collategene)Phase 3Gene therapy / editingHGF (hepatocyte growth factor), Hepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
Cilostazol / Rosuvastatin (UI022 / UI023)Phase 3Small moleculePDE3 (phosphodiesterase 3) and HMG-CoA reductaseReliable signal
NCT07600385: KPAQ summary score change (FAS, n=257): test group 15.41 points (SD 14.18) vs control group 10.27 points (SD 14.70); between-group difference 5.14 points (P=0.004), test group superior.
DalcetrapibPhase 3Small moleculeCETPPartial signal
NCT00658515: Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). missed
NCT01059682: Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS. (24 months): Dalcetrapib 0.6% (Standard Deviation 3.69) vs Placebo 0.5% (Standard Deviation 2.01)
Dapagliflozin (Farxiga / Forxiga)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
DWC202206 + DWC202207Phase 3Small molecule—Partial signalNo reviewed efficacy summary in this indication
EbronucimabPhase 3Monoclonal antibodyPCSK9Partial signal
NCT05255094: LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001).
Enlicitide (Lipfendra)Phase 3PeptidePCSK9Reliable signal
NCT05952856: Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001).
NCT05952869: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24): Enlicitide Decanoate -58.2% (Standard Deviation 28) vs Placebo 2.6% (Standard Deviation 23.6)
Ezetimibe (Zetia)Phase 3Small moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1Reliable signal
NCT00092586: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001)
NCT03867318: Proportion achieving LDL-C goal <=100 mg/dL at Week 14: 22% (ezetimibe 10mg + atorvastatin, n=305) vs 7% (atorvastatin dose-titration alone, n=316); P<.01
Fimasartan / Atorvastatin / Ezetimibe (BR1017)Phase 3Small moleculeAT1 receptor; NPC1L1; HMG-CoA reductasePartial signal
NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025).
HyzetimibePhase 3Small moleculeNPC1L1Partial signal
NCT03433196: LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001
NCT03413462: 第12周试验组LDL-C较基线的变化率为(-10.23±13.58)%,显著优于对照组(4.34±15.88)%。
Inclisiran (Leqvio)Phase 3RNA / oligonucleotidePCSK9Partial signal
NCT04652726: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78)
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
LaroprovstatPhase 3Small moleculePCSK9Reliable signal
NCT06173570: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo)
Laroprovstat / RosuvastatinPhase 3Small moleculePCSK9 (laroprovstat component) + HMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
LepodisiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT05565742: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo)
Lerodalcibep (Lerochol)Phase 3Protein / enzyme therapeuticPCSK9Reliable signal
NCT04797104: LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001)
NCT05004675: LDL-C change from baseline at Day 270 (mITT): -53% with lerodalcibep vs -45.3% with inclisiran (P=0.0319); per-protocol: -55.4% vs -45.4% (P=0.005)
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
MDR-001
Phase 3(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
MuvalaplinPhase 3Small moleculeApolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interactionPartial signal
NCT05563246: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay (Baseline, Week 12): 10 mg LY3473329 -47.35% ± 4.811 vs 60 mg LY3473329 -81.57% ± 1.230 vs 240 mg LY3473329 -85.71% ± 0.927 vs Placebo 0.48% ± 6.382; p=<.001 (10 mg LY3473329 vs Placebo), p=<.001 (60 mg LY3473329 vs Placebo), p=<.001 (240 mg LY3473329 vs Placebo)
NL003Phase 3Gene therapy / editingHepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPPartial signal
NCT05142722: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571)
NCT05425745: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10 mg -36.05% (Standard Error 1.769) vs Placebo 0.25% (Standard Error 2.48)
Obicetrapib / Ezetimibe (Evlarco)Phase 3Small moleculeCETP, NPC1L1Partial signal
NCT06005597: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564)
OlpasiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT04270760: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W)
Ongericimab (Junshida)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT05325203: Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001)
NCT04781114: LDL-C percentage change from baseline to week 24 vs placebo: 150 mg Q2W -67.7% (95% CI -72.5% to -63.0%; P<0.0001); 300 mg Q4W -61.2% (95% CI -67.1% to -55.2%; P<0.0001).
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PelacarsenPhase 3RNA / oligonucleotideApolipoprotein(a) mRNAPartial signal
NCT05305664: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule (Up to Week 52): Pelacarsen (TQJ230) 0.16 Apheresis sessions received per week (IQR 0.04 to 0.25) vs Placebo 0.93 Apheresis sessions received per week (IQR 0.9 to 1)
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signalNo reviewed efficacy summary in this indication
PMR (cilostazol ER)Phase 3Small moleculePhosphodiesterase 3 (PDE3)Weak signalNo reviewed efficacy summary in this indication
PravafenixPhase 3Small moleculeHMG-CoA reductase / PPAR-alphaPartial signalNo reviewed efficacy summary in this indication
QLC7401Phase 3RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
RanolazinePhase 3Small moleculeCardiac late sodium current (late INa, Nav1.5)Partial signal
NCT00099788: The primary end point occurred in 696 patients (21.8%) in the ranolazine group and 753 patients (23.5%) in the placebo group (hazard ratio 0.92). missed
NCT01562041: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index (Baseline up to Day 15): Ranolazine 500 mg — Test 1: 3.211 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.6553); Test 2: 2.822 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0289); Test 3: 3.228 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.891); Test 4: 2.502 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.8884); Change From Baseline in Maximum ST/Heart Rate Index: -0.605 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0482)
RecaticimabPhase 3Monoclonal antibodyPCSK9Reliable signal
NCT04844125: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001
NCT04849000: LDL-C reduction vs placebo at the primary endpoint timepoint: 150 mg Q4W -49.6% (95% CI 44.2-54.9%); 300 mg Q8W -52.8% (95% CI 48.3-57.2%); 450 mg Q12W -45.0% (95% CI 41.0-49.0%); P<0.0001 for all comparisons.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
SAL003Phase 3Monoclonal antibodyPCSK9Partial signalNo reviewed efficacy summary in this indication
Sarpogrelate (Anplag)Phase 3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
SumecigrelPhase 3Small moleculeP2Y12 platelet receptorPartial signal
NCT03599284: Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin.
SYH2053Phase 3RNA / oligonucleotidePCSK9Partial signalNo reviewed efficacy summary in this indication
Tafolecimab (Sintbilo)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT04289285: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001
NCT04709536: Percent change in LDL-C from baseline to Week 12: tafolecimab -68.9% (SE 1.4%) vs placebo -5.8% (SE 1.8%); treatment difference -63.0% (95% CI -66.5% to -59.6%, P<0.0001)
ZiltivekimabPhase 3Monoclonal antibodyInterleukin-6Partial signal
NCT05021835: 3-point MACE (CV death, non-fatal MI, non-fatal stroke): HR 0.99 (95% CI 0.88-1.11) for ziltivekimab vs placebo. missed
Zovaglutide
Phase 3(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
NeovasculgenPhase 2/3Gene therapy / editingVEGF165 gene therapy (angiogenic plasmid)Partial signal
NCT03068585: Pain-free walking distance increased in the pCMV-vegf165 (Neovasculgen) treatment group by 110.4% at 6 months, versus no positive results in the standard-treatment control group
ABP-745Phase 2Small moleculeNLRP3 inflammasomenot yet gradedNo reviewed efficacy summary in this indication
ACP-01Phase 2Biologic (subtype unspecified)Autologous angiogenic cell precursor (ACP) therapyPartial signal
NCT02551679: Primary composite (de-novo gangrene, doubling of wound size, major amputation or death within 1 year): 12 of 46 participants on ACP-01 vs 3 of 21 on placebo, hazard ratio 2.046 (95% CI 0.577 to 7.255), p=0.258 (CT.gov posted results). missed
APACPhase 2PeptideVascular injury site glycocalyx / coagulation cascadenot yet gradedNo reviewed efficacy summary in this indication
BW-20829Phase 2RNA / oligonucleotideLipoprotein(a) [Lp(a)] production pathwaynot yet gradedNo reviewed efficacy summary in this indication
CNIC-Ferrer Polypill (Trinomia)Phase 2Small moleculeMulti-mechanism secondary-prevention polypillPartial signalNo reviewed efficacy summary in this indication
DNV001Phase 2RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
Ecnoglutide (VRB-101)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
EDP167Phase 2RNA / oligonucleotideANGPTL3Weak signalNo reviewed efficacy summary in this indication
Exenatide (PT320)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
TE-8105
Phase 2(overall)
PeptideGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
ZT006
Phase 2(overall)
PeptideGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 1/2Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Weak signal
NCT03381287: Day 28, 2000 mg/day (highest dose) vs placebo: total cholesterol -8.2% (P=0.0004); LDL-C -10.4% (P=0.0006). Lower doses (500 mg, 1000 mg) did not reach significance.
ALN-ANG3Phase 1RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
BMF-650
Phase 1(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
DehydraTECH-CBD / Semaglutide
Phase 1(overall)
CombinationOral peptide delivery platform, GLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
IBI3032
Phase 1(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Liraglutide (HUC2-676)
Phase 1(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08642534
Phase 1(overall)
UndisclosedGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08656795
Phase 1(overall)
UndisclosedGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Semaglutide (DWRX5003)
Phase 1(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
MGL-2086
—(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 83 furthest-along competitors are listed; 56 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(74 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Semaglutide (Ozempic) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (10)
November 2026 (2)
Phase 4Type 2 DiabetesEnrolling by invitation
Est. primary completion 2026-11-30 · NCT06954090 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesNot yet recruiting
Est. primary completion 2026-11-30 · NCT07570810 · CT.gov ↗
What to watch
December 2026 (8)
Phase 2Type 2 DiabetesActive not recruiting
Est. primary completion 2026-12 · NCT05067621 · CT.gov ↗
What to watch
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2026-12 · NCT07059377 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesEnrolling by invitation
Est. primary completion 2026-12 · NCT07677995 · CT.gov ↗
What to watch
Phase 2Type 2 DiabetesActive not recruiting
Est. primary completion 2026-12-31 · NCT06005012 · CT.gov ↗
What to watch
Phase 2Intestinal Mucositis, Inflammation, Chemotherapeutic ToxicityNot yet recruiting
Est. primary completion 2026-12-31 · NCT06449625 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2026-12-31 · NCT06461377 · CT.gov ↗
What to watch
Phase 4Diabetes Mellitus, Cardiovascular Diseases, Cerebrovascular DiseaseEnrolling by invitation
Est. primary completion 2026-12-31 · NCT06959784 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2026-12-31 · NCT07165158 · CT.gov ↗
What to watch
2027 (26)
January 2027 (4)
Phase 2Cocaine Use Disorder, HIVActive not recruiting
Est. primary completion 2027-01 · NCT06691243 · CT.gov ↗
What to watch
Phase 3Diabetes Type 1Recruiting
Est. primary completion 2027-01 · NCT06894784 · CT.gov ↗
What to watch
Phase 2Methamphetamine Use DisorderNot yet recruiting
Est. primary completion 2027-01 · NCT07509112 · CT.gov ↗
What to watch
Phase 4Psoriasis ArthritisNot yet recruiting
Est. primary completion 2027-01-01 · NCT07251556 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1Alcohol Use Disorder, Weight Loss, Bariatric Surgery PatientsActive not recruiting
Est. primary completion 2027-02 · NCT07223983 · CT.gov ↗
What to watch
March 2027 (2)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-03-08 · NCT07314684 · CT.gov ↗
What to watch
Phase 2Addiction, Alcohol Use DisorderActive not recruiting
Est. primary completion 2027-03-31 · NCT06015893 · CT.gov ↗
What to watch
April 2027 (5)
Phase 4Cardiovascular DiseasesNot yet recruiting
Est. primary completion 2027-04 · NCT07483801 · CT.gov ↗
What to watch
Phase 4Atrial Fibrillation, Obesity, Weight LossActive not recruiting
Est. primary completion 2027-04-10 · NCT06184633 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-04-30 · NCT05071898 · CT.gov ↗
What to watch
Phase 3Klinefelter SyndromeRecruiting
Est. primary completion 2027-04-30 · NCT05586802 · CT.gov ↗
What to watch
Phase 2Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders …Recruiting
Est. primary completion 2027-04-30 · NCT06548490 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-06 · NCT05822609 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesRecruiting
Est. primary completion 2027-06 · NCT07317115 · CT.gov ↗
What to watch
Phase 2Alcohol Use Disorder (AUD), HIVRecruiting
Est. primary completion 2027-06-30 · NCT07040592 · CT.gov ↗
What to watch
July 2027 (2)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-07 · NCT07017270 · CT.gov ↗
What to watch
Phase 3Acute Ischemic StrokeNot yet recruiting
Est. primary completion 2027-07-31 · NCT07030621 · CT.gov ↗
What to watch
September 2027 (2)
Phase 4Type 2 DiabetesActive not recruiting
Est. primary completion 2027-09 · NCT06042153 · CT.gov ↗
What to watch
Phase 2Opioid Use DisorderRecruiting
Est. primary completion 2027-09-01 · NCT06639464 · CT.gov ↗
What to watch
October 2027 (3)
Phase 3Diabetes Mellitus, Type 1Recruiting
Est. primary completion 2027-10-01 · NCT05819138 · CT.gov ↗
What to watch
Phase 2Kidney Transplant RecipientsRecruiting
Est. primary completion 2027-10-01 · NCT05938712 · CT.gov ↗
What to watch
Phase 4Prostate CancerActive not recruiting
Est. primary completion 2027-10-31 · NCT06908694 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Type 2 DiabetesActive not recruiting
Est. primary completion 2027-11-07 · NCT03811561 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2/3Type 1 Diabetes, Diabetes MellitusRecruiting
Est. primary completion 2027-12 · NCT06387199 · CT.gov ↗
What to watch
Early phase / not applicableCaloric Restriction, Body Composition, PerformanceNot yet recruiting
Est. primary completion 2027-12-30 · NCT07874932 · CT.gov ↗
What to watch
Early phase / not applicableCaloric Restriction, Body Composition, PerformanceNot yet recruiting
Est. primary completion 2027-12-31 · NCT07874971 · CT.gov ↗
What to watch
2028 (21)
January 2028 (1)
Phase 2Type 1 Diabetes MellitusNot yet recruiting
Est. primary completion 2028-01-31 · NCT07614412 · CT.gov ↗
What to watch
February 2028 (2)
Phase 3Acute Ischemic Stroke, Large Vessel Occlusion, Neuroprotective Drugs, Endovascular TreatmentNot yet recruiting
Est. primary completion 2028-02 · NCT06788626 · CT.gov ↗
What to watch
Phase 3PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, ObeseRecruiting
Est. primary completion 2028-02-01 · NCT05819853 · CT.gov ↗
What to watch
April 2028 (3)
Phase 2Prostate Carcinoma, Recurrent Prostate CarcinomaRecruiting
Est. primary completion 2028-04-09 · NCT07202247 · CT.gov ↗
What to watch
Phase 2Diabetes type1, ObesityRecruiting
Est. primary completion 2028-04-30 · NCT06411210 · CT.gov ↗
What to watch
Phase 2Cannabis Use Disorder, Cannabis Use Disorders, Cannabis Abuse, Cannabis Dependence, Cannabis AddictionRecruiting
Est. primary completion 2028-04-30 · NCT07523633 · CT.gov ↗
What to watch
May 2028 (3)
Phase 1/2Type 2 DiabetesRecruiting
Est. primary completion 2028-05 · NCT07563699 · CT.gov ↗
What to watch
Phase 4Tobacco UseRecruiting
Est. primary completion 2028-05-30 · NCT06986993 · CT.gov ↗
What to watch
Phase 2Weight GainRecruiting
Est. primary completion 2028-05-31 · NCT07325500 · CT.gov ↗
What to watch
June 2028 (3)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-06 · NCT07239570 · CT.gov ↗
What to watch
Phase 2Intracerebral HemorrhageNot yet recruiting
Est. primary completion 2028-06-14 · NCT07613437 · CT.gov ↗
What to watch
Phase 1Pancreatic Cancer, Colorectal Cancer, Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT07627191 · CT.gov ↗
What to watch
July 2028 (2)
Early phase / not applicableType 2 DiabetesRecruiting
Est. primary completion 2028-07-31 · NCT07065383 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2028-07-31 · NCT07073053 · CT.gov ↗
What to watch
August 2028 (1)
Phase 3Double DiabetesRecruiting
Est. primary completion 2028-08 · NCT05305794 · CT.gov ↗
What to watch
September 2028 (3)
Phase 4Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2028-09 · NCT07617155 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2028-09-01 · NCT06706284 · CT.gov ↗
What to watch
Phase 2/3Type 1 Diabetes, Overweight , ObesityRecruiting
Est. primary completion 2028-09-01 · NCT07891156 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Ischemic StrokeNot yet recruiting
Est. primary completion 2028-10-31 · NCT07511543 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2028-11 · NCT07428746 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2028-12 · NCT07581145 · CT.gov ↗
What to watch
2029 (11)
January 2029 (2)
Phase 2Cocaine Use DisorderRecruiting
Est. primary completion 2029-01-28 · NCT07227948 · CT.gov ↗
What to watch
Phase 2Cannabis Use Disorder, Cue-reactivityNot yet recruiting
Est. primary completion 2029-01-30 · NCT07879612 · CT.gov ↗
What to watch
March 2029 (2)
Phase 3Alcohol Use DisorderRecruiting
Est. primary completion 2029-03-31 · NCT07218354 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesEnrolling by invitation
Est. primary completion 2029-03-31 · NCT07547878 · CT.gov ↗
What to watch
April 2029 (1)
Phase 4Atrial Fibrillation (AF)Not yet recruiting
Est. primary completion 2029-04 · NCT07389941 · CT.gov ↗
What to watch
May 2029 (1)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2029-05-01 · NCT07485062 · CT.gov ↗
What to watch
June 2029 (2)
Phase 1/2Alzheimer Dementia (AD)Recruiting
Est. primary completion 2029-06 · NCT07651319 · CT.gov ↗
What to watch
Phase 2Stage 1 Diabetes Mellitus, Type 1Not yet recruiting
Est. primary completion 2029-06-01 · NCT07430332 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Cardiovascular Diseases, Heart Failure, Type 1 Diabetes, Kidney FailureRecruiting
Est. primary completion 2029-07-01 · NCT06082063 · CT.gov ↗
What to watch
December 2029 (2)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2029-12-20 · NCT07900438 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2029-12-31 · NCT06058585 · CT.gov ↗
What to watch
2030 (5)
February 2030 (1)
Phase 2Methamphetamine-dependenceRecruiting
Est. primary completion 2030-02-15 · NCT07204249 · CT.gov ↗
What to watch
March 2030 (1)
Phase 3Glucose Intolerance After a Recent History of Gestational DiabetesRecruiting
Est. primary completion 2030-03 · NCT05569772 · CT.gov ↗
What to watch
May 2030 (1)
Phase 4Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol ExcessRecruiting
Est. primary completion 2030-05-31 · NCT07361874 · CT.gov ↗
What to watch
July 2030 (2)
Early phase / not applicableSevere Mental Illness, Depression / Major Depressive Disorder, Bipolar Disorder (BD), SchizophreniaNot yet recruiting
Est. primary completion 2030-07 · NCT07586150 · CT.gov ↗
What to watch
Phase 3Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk, Insulin ResistanceNot yet recruiting
Est. primary completion 2030-07-30 · NCT07770282 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 1Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)Recruiting
Est. primary completion 2031-10-31 · NCT07772960 · CT.gov ↗
What to watch

See the full readout calendar ↗